U.S., May 22 -- ClinicalTrials.gov registry received information related to the study (NCT06981754) titled 'Dexamethasone Palmitate for PONV After Minimally Invasive Endoscopic Surgery' on May 13.
Brief Summary: Dexamethasone is almost one of the most commonly used drugs for postoperative nausea and vomiting (PONV) prevention. However, PONV is still a complex problem to be solved; for example, even with preoperative dexamethasone administration, 14.0-26.3% of patients undergoing minimally invasive endoscopic procedures still experience PONV within 24 hours postoperatively. Compared to dexamethasone, dexamethasone palmitate has a long-lasting anti-inflammatory effect, 2-5 times that of traditional water-soluble dexamethasone, with fewer adv...